Compound Planning Inc. Has $667,000 Stock Holdings in Novo Nordisk A/S $NVO

Compound Planning Inc. trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 40.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,137 shares of the company’s stock after selling 12,200 shares during the quarter. Compound Planning Inc.’s holdings in Novo Nordisk A/S were worth $667,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Capital Investment Counsel LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter worth about $3,727,000. Marathon Capital Management grew its stake in Novo Nordisk A/S by 43.9% during the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock valued at $4,208,000 after acquiring an additional 25,230 shares in the last quarter. Banque Pictet & Cie SA increased its holdings in shares of Novo Nordisk A/S by 68.2% in the 4th quarter. Banque Pictet & Cie SA now owns 86,648 shares of the company’s stock valued at $4,409,000 after purchasing an additional 35,142 shares during the period. Burney Co. purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $1,374,000. Finally, Burkett Asset Management Ltd purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $1,823,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Finally, HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $49.63 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm has a market cap of $221.58 billion, a PE ratio of 11.65, a PEG ratio of 4.45 and a beta of 0.77. The firm’s 50 day moving average price is $46.46 and its 200 day moving average price is $45.63. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $71.28.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, research analysts expect that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.